Centrally Acting Antiemetic and Prokinetic

Dopamine-2 Antagonist; antagonizes dopamine in the GI tract and chemoreceptor trigger zone. Domperidone increases lower oesophageal sphincter  pressure. A similar mechanism of action to Metoclopramide, but with fewer adverse CNS effects as it doesn't pass through the blood-brain barrier.

• Anti-emetic: Treatment of vomiting.

• Prokinetic/Gastrokinetic: Used in small herbivores with gut stasis.  

• Stimulation of lactation: May be used to stimulate milk production in horses and small animals.

Peripheral Actions

• Dopamine Antagonist: Anti-emetic properties, active in the CTZ and GI tract

• Alpha1 and Beta Antagonist: Active in the stomach

Hepatic Metabolism

• Mechanism: Domperidone undergoes rapid and extensive hepatic metabolism by hydroxylation and N-dealkylation.  

• Pathway: CYP3A4 is a major form of cytochrome P-450 involved in the N-dealkylation of Domperidone, whereas CYP3A4, CYP1A2 and CYP2E1 are involved in Domperidone aromatic hydroxylation.

Mixed Biliary and Urinary Excretion

• Metabolites: Metabolites are excreted in the faeces and urine.

1. Ahmad, N., Keith-Ferris, J., Gooden, E., Abell, T., 2006. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 6, 571–576. https://doi.org/10.1016/j.coph.2006.07.004

2. Al-Khamis, K.I., Kaka, J.S., Matar, K.M., 1987. Effect of domperidone on cimetidine and ranitidine absorption in rabbits. Biopharm Drug Dispos 8, 319–325. https://doi.org/10.1002/bdd.2510080403

3. Barone, J.A., 1999. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother 33, 429–440. https://doi.org/10.1345/aph.18003

4. Champion, M.C., Hartnett, M., Yen, M., 1986. Domperidone, a new dopamine antagonist. CMAJ 135, 457–461.

5. Delpierre, S., Peyrot, J., Guillot, C., Grimaud, C., 1985. Ventilatory effects of domperidone, a new dopamine antagonist, in anaesthetized rabbits. Arch Int Pharmacodyn Ther 275, 47–58.

6. Doggrell, S.A., Hancox, J.C., 2014. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine. Expert Opin Drug Saf 13, 131–138. https://doi.org/10.1517/14740338.2014.851193

7. Frommeyer, G., Fischer, C., Ellermann, C., Lange, P.S., Dechering, D.G., Kochhäuser, S., Fehr, M., Eckardt, L., 2017. Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone. Cardiovasc. Toxicol. 17, 451–457. https://doi.org/10.1007/s12012-017-9403-5

8. Haans, J.J.L., Masclee, A. a. M., 2007. Review article: The diagnosis and management of gastroparesis. Aliment. Pharmacol. Ther. 26 Suppl 2, 37–46. https://doi.org/10.1111/j.1365-2036.2007.03534.x

9. Hofmeyr, G.J., van Iddekinge, B., 1983. Domperidone and lactation. Lancet 1, 647. https://doi.org/10.1016/s0140-6736(83)91818-4

10. Kilbinger, H., Weihrauch, T.R., 1982. Drugs increasing gastrointestinal motility. Pharmacology 25, 61–72. https://doi.org/10.1159/000137725

11. Leeser, J., Bateman, D.N., 1985. Domperidone. Br Med J (Clin Res Ed) 290, 241.

12. Li, C., Qian, W., Hou, X., 2009. Effect of Four Medications Associated with Gastrointestinal Motility on Oddi Sphincter in the Rabbit. Pancreatology 9, 615–620. https://doi.org/10.1159/000212095

13. Madisch, A., Vinson, B.R., Abdel-Aziz, H., Kelber, O., Nieber, K., Kraft, K., Storr, M., 2017. Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr 167, 160–168. https://doi.org/10.1007/s10354-017-0557-3

14. Mt-Isa, S., Tomlin, S., Sutcliffe, A., Underwood, M., Williamson, P., Croft, N.M., Ashby, D., 2015. Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide. J. Pediatr. Gastroenterol. Nutr. 60, 508–514. https://doi.org/10.1097/MPG.0000000000000657

15. Oosterveld, W.J., 1981. Vestibular pharmacology of domperidone in rabbits and man. ORL J Otorhinolaryngol Relat Spec 43, 175–180. https://doi.org/10.1159/000275537

16. Patterson, D., Abell, T., Rothstein, R., Koch, K., Barnett, J., 1999. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am. J. Gastroenterol. 94, 1230–1234. https://doi.org/10.1111/j.1572-0241.1999.00456.x

17. Phan, H., DeReese, A., Day, A.J., Carvalho, M., 2014. The dual role of domperidone in gastroparesis and lactation. Int J Pharm Compd 18, 203–207.

18. Reddymasu, S.C., Soykan, I., McCallum, R.W., 2007. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 102, 2036–2045. https://doi.org/10.1111/j.1572-0241.2007.01255.x

19. Robinson, P., 2008. Dosage and drug interactions of domperidone. Am J Gastroenterol 103, 1049. https://doi.org/10.1111/j.1572-0241.2007.01772_12.x

20. Schapira, M., Henrion, J., Heller, F.R., 1990. The current status of gastric prokinetic drugs. Acta Gastroenterol. Belg. 53, 446–457.

21. Smolina, K., Mintzes, B., Hanley, G.E., Oberlander, T.F., Morgan, S.G., 2016. The association between domperidone and ventricular arrhythmia in the postpartum period. Pharmacoepidemiol Drug Saf 25, 1210–1214. https://doi.org/10.1002/pds.4035

22. Templeton, I., Ravenstijn, P., Sensenhauser, C., Snoeys, J., 2016. A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4. Biopharm Drug Dispos 37, 15–27. https://doi.org/10.1002/bdd.1992

23. Valenzuela, J.E., Dooley, C.P., 1984. Dopamine antagonists in the upper gastrointestinal tract. Scand J Gastroenterol Suppl 96, 127–136.

24. van Roeden, S.E., Belle-van Meerkerk, G., van Tuyl, S.A.C.B., van de Ree, M.A., Muller, A.F., 2013. [Domperidone and the risk of sudden cardiac death]. Ned Tijdschr Geneeskd 157, A6770.

25. Wauquier, A., Niemegeers, C.J., Janssen, P.A., 1981. Neuropharmacological comparison between domperidone and metoclopramide. Jpn J Pharmacol 31, 305–314. https://doi.org/10.1254/jjp.31.305

Phase 1 Author(s)

*McArthur, S .D.J. MRCVS  (01/04/2022)

1. Data: Primary Data

2. User Interface: Primary Data

3. Evidence Grade: Primary Grade (Scale)

4. Efficacy Rating: Primary Rating (Colour)

Phase 1 Analyst(s)

Invitation Analyst 1: Contribution is welcomed.

• No invitation analysis is available at present

Phase 2 Analyst(s)

Community Analyst 1:  Contribution is welcomed.

• No content analysis is available at present

Contribute

Please comment upon the content here and offer colleagues the benefit of any additional information you feel will improve clinical practices. Contribution is always appreciated.

You can always reach us via the email link displayed at the foot of every page. Some pages may also contain additional routes to contribution. They will either be available as a hyperlink or via an analysis link displayed as an analysis icon (🔍). These typically link to a form with defined contribution fields.

Recognition of Contribution

Colleagues whose contributions modify the monograph are recorded within validation data, along with a description of the contribution and the contribution date.